Verastem's Strong Commercial Performance and Growth Potential Reinforce Buy RatingWe view the sell-off as disconnected from fundamentals. The IDMC’s minor adjustment aligns with faster-than-expected accrual and event count. Launch metrics remain robust, with further upside as NCCN updates and early off-label use expand the addressable market. Meanwhile, VS-7375 continues to look potentially best-in-class in G12D, supported by improved tolerability, strong efficacy data, and ongoing industry validation. With solid execution, multiple 1H26 catalysts, and a cash runway into 2H26, we reiterate our Buy rating and $20 price target, viewing the pullback as an attractive entry point ahead of upcoming catalysts.